Up
2005P-0464:
Remove Metered-dose Inhalers (MDI) Containing the Single Active
Moieties Beclomethasone, Fluticasone, and Salmeterol, Respectively,
from the Essential-use List of Ozone-depleting Substance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
| CP1
|
| 11/15/2005
|
| 11/15/2005
|
| Private Industry
|
| GlaxoKline
|
|
|
|
|
|
|
| pdf
|
|
|
|
| Signature:
|
| James A. Losey, Esq.
|
|
|
| ACK1
|
| 11/15/2005
|
| 11/15/2005
|
| Federal
Government
|
| HFA-305 to GlaxoKline
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Jennic C. Butler
|
|
| |
|
|
|
Top | Up
Page last updated
December 7, 2005
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |